Pami Taylor, MD
Internal Medicine · Tupelo, MSNPI 1477592632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 714 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$1K
- AbbVie$1K
- Pfizer$1K
- Amgen$852
- Johnson & Johnson$669
- plus $4K from 33 others
What the payments were for
- Food & beverage$10,275100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$103
- JARDIANCE$101
How this compares
$10,289 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 264 | $285,807 |
| FarxigaDapagliflozin Propanediol | 326 | $274,504 |
| OzempicSemaglutide | 201 | $233,901 |
| MounjaroTirzepatide | 109 | $154,364 |
| EliquisApixaban | 128 | $119,189 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 231 | $70,376 |
| XareltoRivaroxaban | 49 | $45,278 |
| RybelsusSemaglutide | 19 | $31,761 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $30,705 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 127 | $27,998 |
| MyrbetriqMirabegron | 29 | $26,506 |
| InvokanaCanagliflozin | 27 | $21,910 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $15,649 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $12,333 |
| EntrestoSacubitril/Valsartan | 16 | $11,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $566 | $285,807264 claims |
| AstraZenecaFarxiga, Symbicort | $1,158 | $278,698345 claims |
| Novo NordiskOzempic, Rybelsus | $258 | $265,662220 claims |
| Lilly USA, LLCMounjaro | $1,092 | $154,364109 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $390 | $154,345464 claims |
| PfizerEliquis | $1,025 | $119,189128 claims |
| Johnson & JohnsonXarelto, Invokana | $669 | $67,18876 claims |
| Astellas Pharma US IncMyrbetriq | $283 | $26,50629 claims |
| AbbVieSynthroid | $1,042 | $10,784104 claims |
| MerckJanuvia | $169 | $5,90411 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $210 | $3,24527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Tupelo
- Jonathan BlossomTupelo$11K
- Vernon RayfordTupelo$7K
- Henry BolerTupelo$7K
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.